C Marín Hernández1,2, A Piñero Madrona3, P J Gil Vázquez3, P J Galindo Fernández3, G Ruiz Merino3, J L Alonso Romero3, P Parrilla Paricio3. 1. Breast Unit, Service of General Surgery, University Hospital Virgen de la Arrixaca, Carretera Madrid-Cartagena s/n, 30120, Murcia, Spain. carikimh@gmail.com. 2. Department of Surgery, University Hospital Virgen de la Arrixaca, Murcia, Spain. carikimh@gmail.com. 3. Breast Unit, Service of General Surgery, University Hospital Virgen de la Arrixaca, Carretera Madrid-Cartagena s/n, 30120, Murcia, Spain.
Abstract
BACKGROUND: Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT. METHODS: A retrospective cohort of 150 breast cancer patients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS). RESULTS: Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress. CONCLUSION: High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT.
BACKGROUND: Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT. METHODS: A retrospective cohort of 150 breast cancerpatients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS). RESULTS:Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress. CONCLUSION: High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT.
Entities:
Keywords:
Breast cancer; Lymphocyte-to-monocyte ratio; Neoadjuvant chemotherapy; Neutrophil-to-lymphocyte ratio; Neutrophil-to-monocyte ratio
Authors: Di Sun; Paul Elson; Michaela Liedtke; Bruno C Medeiros; Marc Earl; Ash Alizadeh; Jennifer Bates; Mikkael A Sekeres; Steven Coutre; Matt Kalaycio; Ronald Sobecks; Edward Copelan; Anjali S Advani Journal: Am J Hematol Date: 2012-06-22 Impact factor: 10.047
Authors: Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys Journal: Breast Date: 2003-10 Impact factor: 4.380
Authors: A Bergamaschi; E Tagliabue; T Sørlie; B Naume; T Triulzi; R Orlandi; H G Russnes; J M Nesland; R Tammi; P Auvinen; V-M Kosma; S Ménard; A-L Børresen-Dale Journal: J Pathol Date: 2008-02 Impact factor: 7.996
Authors: Javier Valdés-Ferrada; Natalia Muñoz-Durango; Alejandra Pérez-Sepulveda; Sabrina Muñiz; Irenice Coronado-Arrázola; Francisco Acevedo; Jorge A Soto; Susan M Bueno; Cesar Sánchez; Alexis M Kalergis Journal: Front Immunol Date: 2020-07-09 Impact factor: 7.561